Results 101 to 110 of about 13,218 (206)

Influence of Darunavir: β-cyclodextrin complex on the solubility of Darunavir

, 2016
Fundação de Amparo à Pesquisa do Estado de São Paulo (FAPESP)
Kogawa, Ana Carolina, Corrêa, Josilene Chaves Ruela, Salgado, Hérida Regina Nunes   +2 more
openaire   +1 more source

Therapeutic drug monitoring uncovering incorrect antiretroviral drug intake in a patient with swallowing difficulties. [PDF]

IDCases
Carrozzo G, Cattaneo D, Giacomelli A, Gori A, Ridolfo AL, Gervasoni C, Cossu MV.   +6 more
europepmc   +1 more source

Persistent low-level viremia and symptomatic HIV cerebrospinal fluid escape in a person living with HIV receiving darunavir: a case report. [PDF]

Braz J Infect Dis
Suriano ES, Kuslevicius K, Leal MMDS, Relvas LFD, Schneider GAR.   +4 more
europepmc   +1 more source

Development of qualitative analytical methods for monitoring darunavir tablets

, 2013
Darunavir is a protease inhibitor used in the treatment of HIV infection. It is a pillar of the drug cocktail for patients diagnosed with the virus. Quality control in the pharmaceutical industry, to verify the content of active substance and study the ...
Salgado, Hérida Regina Nunes [UNESP], Carolina Kogawa, Ana [UNESP]   +1 more
core  

Late-stage Diversification of HIV-1 Protease Inhibitor via SuFEx Click Chemistry. [PDF]

Synthesis (Stuttg)
Khanal B, Yamanushkin P, Gold B.
europepmc   +1 more source

Darunavir and Fosamprenavir Inhibit Zika Virus Replication via Dual Targeting of the Envelope Protein and NS2B-NS3 Protease. [PDF]

J Med Virol
Kan JY, Su HC, Lai HC, Lin YF, Chiu SW, Wu PC, Hsueh PR, Lu CH, Lin CW.   +8 more
europepmc   +1 more source

Multiclass HIV drug resistance: Case series of treatment-experienced PLHIV with resistance to all antiretroviral classes in Northern Uganda. [PDF]

IDCases
Kayinda F, Bakunzi LB, Okello E, Jurua C, Nasuuna EM.   +4 more
europepmc   +1 more source

Physiologically Based Pharmacokinetic Modeling to Assess Antiretroviral-BTK Inhibitor Interactions and Provide Recommendations for Co-Administration Regimens. [PDF]

Pharmaceutics
Chen L, Wang X, Li L, Yang Y, Liu Y, Chen W.   +5 more
europepmc   +1 more source

Occult hepatitis B and risk of reactivation following switch to non-hepatitis B virus-active antiretroviral therapy in people with HIV. [PDF]

AIDS
Lapadula G, Soria A, Puoti M, Bonfanti P.   +3 more
europepmc   +1 more source

Dolutegravir restores gut microbiota in late-stage HIV-1 unlike darunavir: an open-label, randomized clinical trial. [PDF]

Nat Commun
Català-Moll F, Blázquez-Bondia C, Farré-Badia J, Torres F, Manzardo C, Bonfill E, Curran A, Domingo P, Podzamczer D, Force L, Falcó V, Parera M, Casadellà M, Miró JM, Noguera-Julian M, Paredes R, ADVANZ-4 MISTRAL investigators.   +16 more
europepmc   +1 more source